Document Type: Press Releases

PFD Annouces Completion of the First-in-Human iKnee Implantation

PFD Capital Partners, Inc. announced the successful completion of the first-in-human implantation of the investigational iKnee on July 31, 2026, at Prime Surgical Center of Newport Beach, marking the start of the device’s human clinical evaluation. The patient-specific implant, developed by PFD iOrthopedics from Robert Thomas Grotz, MD’s patented Resilient Arthroplasty Device (RAD) technology, is […]

PFD Announces July 31 First-in-Human Implantation of the iKnee

PFD Capital Partners announced the scheduled July 31, 2026, first-in-human implantation of the investigational iKnee at Prime Surgical Center of Newport Beach. The outpatient procedure will be performed by principal investigator Dr. Christopher Woodson, with PFD Director of Clinical Operations Eric Hansen serving as the first patient. The milestone begins the iKnee’s human clinical evaluation […]

PFD Highlights Dr. Daniel Rastein’s Invitation to Participate in FDA Patient-Focused Drug Development Meeting on Nonhealing Chronic Wounds

PFD Capital Partners announced that Dr. Daniel Rastein, Founder and CEO of CassdermaRx, has been invited to participate in the FDA’s upcoming Patient-Focused Drug Development public meeting on nonhealing chronic wounds. The meeting is intended to gather patient and caregiver perspectives on the real-world burden of chronic wounds, current treatment challenges, meaningful outcomes, and clinical […]

PFD Announces Regeneration Biomedical’s FDA Fast Track Designation and Phase IIa Trial Site Selections

PFD Capital Partners announced that Regeneration Biomedical, Inc. received FDA Fast Track designation for RB-ADSC, its investigational autologous adipose-derived stem cell therapy for mild to moderate Alzheimer’s disease, and selected multiple Phase IIa clinical trial sites to support a larger randomized, placebo-controlled evaluation of the treatment. The release explains that RB-ADSC uses Wnt-activated adipose-derived stem […]

PFD Highlights Regeneration Biomedical’s Presentation at ISCT 2026 Annual Meeting

PFD Capital Partners announced that portfolio company Regeneration Biomedical, Inc. presented newly reported clinical findings at the ISCT 2026 Annual Meeting in Dublin, Ireland, highlighting its direct-to-brain regenerative therapy platform for Alzheimer’s disease and other neurodegenerative conditions. The release focuses on completed Phase I findings showing reductions and normalization trends in Alzheimer’s-related biomarkers, including CSF […]

PFD Capital Partners Announces Closing of PFDSelect Medical Receivables 1018, LLC

PFD Capital Partners announced the closing of PFDSelect Medical Receivables 1018, LLC, the 17th special purpose entity in PFD’s 1000 Series focused on Personal Injury Medical Accounts Receivable financing. PFDSMR1018 launched on March 11, 2026, and closed to new investments on May 18, 2026, with participation from 99 investors, including 75 new investors, 34 referral-based […]

PFD Announces The U.S., Patent Office Has Granted Regeneration Biomedical, Inc. A New Patent For Its CEREWiNT™ Technology Platform

Irvine, CA. March 17, 2026 — PFD Capital Partners, Inc. (PFD) today announced that Regeneration Biomedical, Inc. (RBI) has been awarded U.S. Patent No. 12,529,034 B2, titled “WNT-Activated Adipose-Derived Stem Cell Apparatus, Methods and Systems.” The newly granted patent significantly expands RBI’s intellectual property portfolio and further positions the company at the forefront of regenerative […]

PFD Announces That Cassderma Rx Has Received FDA Preliminary Clearance to Advance Directly Into Phase 2 Clinical Trials Pending Completion of GLP Toxicology and GMP Ingredient Studies

Irvine, CA — December 19, 2025: Cassderma Rx, a California-based biotech company, has received preliminary FDA clearance to advance its patented wound-healing therapy, CAS101, directly into Phase 2 clinical trials—bypassing traditional Phase 1 requirements. This fast-track decision reflects the therapy’s strong preclinical safety profile and addresses a major unmet need in chronic wound care, which […]

PFD Capital Partners Congratulates Dr. Christopher Woodson On Completion of his 1,000th Mako SmartRobotics™ Joint Replacement

Irvine, CA — December 2, 2025: PFD Capital Partners congratulates Christopher Woodson, MD, on completing his 1,000th Mako Robotic Joint Replacement, marking a major milestone in his distinguished orthopedic career. As PFD’s Principal Investigator for Clinical Operations, Dr. Woodson has been key in developing the patented iKnee™ Resurfacing System, a less invasive, cartilage-preserving alternative to […]